MXPA04006139A - Pirrolidin-2-onas como inhibidores del factor xa. - Google Patents

Pirrolidin-2-onas como inhibidores del factor xa.

Info

Publication number
MXPA04006139A
MXPA04006139A MXPA04006139A MXPA04006139A MXPA04006139A MX PA04006139 A MXPA04006139 A MX PA04006139A MX PA04006139 A MXPA04006139 A MX PA04006139A MX PA04006139 A MXPA04006139 A MX PA04006139A MX PA04006139 A MXPA04006139 A MX PA04006139A
Authority
MX
Mexico
Prior art keywords
alkyl
oxopyrrolidin
halogen
found
mass spectrum
Prior art date
Application number
MXPA04006139A
Other languages
English (en)
Spanish (es)
Inventor
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MXPA04006139A publication Critical patent/MXPA04006139A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
MXPA04006139A 2001-12-21 2002-12-20 Pirrolidin-2-onas como inhibidores del factor xa. MXPA04006139A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0130705.7A GB0130705D0 (en) 2001-12-21 2001-12-21 Chemical compounds
PCT/EP2002/014826 WO2003053925A1 (en) 2001-12-21 2002-12-20 Pyrrolidine-2-ones as factor xa inhibitors

Publications (1)

Publication Number Publication Date
MXPA04006139A true MXPA04006139A (es) 2004-11-01

Family

ID=9928210

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006139A MXPA04006139A (es) 2001-12-21 2002-12-20 Pirrolidin-2-onas como inhibidores del factor xa.

Country Status (23)

Country Link
US (1) US20050059726A1 (https=)
EP (1) EP1456172A1 (https=)
JP (1) JP2005519885A (https=)
KR (1) KR20040072666A (https=)
CN (1) CN100364971C (https=)
AR (1) AR037928A1 (https=)
AU (1) AU2002366747A1 (https=)
BR (1) BR0215200A (https=)
CA (1) CA2471461A1 (https=)
CO (1) CO5590896A2 (https=)
GB (1) GB0130705D0 (https=)
HU (1) HUP0500137A2 (https=)
IL (1) IL162454A0 (https=)
IS (1) IS7316A (https=)
MX (1) MXPA04006139A (https=)
MY (1) MY141579A (https=)
NO (1) NO20042990L (https=)
NZ (1) NZ533129A (https=)
PL (1) PL371008A1 (https=)
RU (1) RU2318807C2 (https=)
TW (1) TWI262075B (https=)
WO (1) WO2003053925A1 (https=)
ZA (1) ZA200404147B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307667A (en) 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
JP2006527732A (ja) 2003-06-19 2006-12-07 グラクソ　グループ　リミテッド Ｘａ因子の阻害剤としての３−スルホニルアミノ−ピロリジン−２−オン誘導体
GB0314373D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314299D0 (en) 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
GB0314370D0 (en) * 2003-06-19 2003-07-23 Glaxo Group Ltd Chemical compounds
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
PE20060574A1 (es) * 2004-07-28 2006-06-24 Glaxo Group Ltd Derivados de arilpiperazina sulfonamida como agonistas de los receptores de secretagogos de la hormona del crecimiento (ghs)
DE102004062544A1 (de) * 2004-12-24 2006-07-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verewendung als Arzneimittel
DE102005008649A1 (de) * 2005-02-25 2006-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Pyrrolidinone, deren Herstellung und deren Verwendung als Arzneimittel
US20090099231A1 (en) * 2005-04-11 2009-04-16 John David Harling 3-Sulfonylamino-Pyrrolidine-2-One Derivatives as Factor Xa Inhibitors
EP1894930A4 (en) 2005-06-23 2010-06-23 Kyowa Hakko Kirin Co Ltd THIAZOLE DERIVATIVE
US7928098B2 (en) 2005-08-02 2011-04-19 Kyowa Hakko Kirin Co., Ltd. Therapeutic and/or preventive agents for a sleep disorder
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
EP1951712A2 (en) * 2005-11-24 2008-08-06 Glaxo Group Limited Chemical compounds
ES2379989T3 (es) 2006-04-07 2012-05-07 Bactiguard Ab Sustratos antimicrobianos novedosos y usos de los mismos
CA2662574A1 (en) * 2006-09-22 2008-03-27 Novartis Ag Heterocyclic organic compounds
CN116003280B (zh) * 2022-12-30 2024-11-19 合肥工业大学 一种芳基甲酰胺类化合物的光化学合成方法
CN116712596A (zh) * 2023-05-30 2023-09-08 北京福爱乐科技发展有限公司 一种用于体内创面喷涂型医用胶及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202344A (en) * 1990-12-11 1993-04-13 G. D. Searle & Co. N-substituted lactams useful as cholecystokinin antagonists
EP1384725A3 (en) * 1994-04-26 2007-02-21 Aventis Pharmaceuticals Inc. Factor Xa inhibitors
US6034093A (en) * 1995-06-07 2000-03-07 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds
US5731315A (en) * 1995-06-07 1998-03-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds
DE69718194T2 (de) * 1996-08-16 2003-10-16 Bristol-Myers Squibb Pharma Co., Wilmington Amidinophenyl-pyrrolidine, -pyrroline und -isoxazolidine und ihre derivate
GB9715894D0 (en) * 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic derivatives
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6025358A (en) * 1998-06-11 2000-02-15 G. D. Searle & Co. Double prodrugs of potent GP IIb/IIIa antagonists
GB0114005D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
TW200307667A (en) * 2002-05-06 2003-12-16 Bristol Myers Squibb Co Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
US7169795B2 (en) * 2003-09-30 2007-01-30 Bristol Myers Squibb Company Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors

Also Published As

Publication number Publication date
AR037928A1 (es) 2004-12-22
CN100364971C (zh) 2008-01-30
WO2003053925A1 (en) 2003-07-03
NZ533129A (en) 2006-12-22
IS7316A (is) 2004-06-16
US20050059726A1 (en) 2005-03-17
TW200306178A (en) 2003-11-16
JP2005519885A (ja) 2005-07-07
CN1620434A (zh) 2005-05-25
RU2004122427A (ru) 2006-01-20
KR20040072666A (ko) 2004-08-18
HUP0500137A2 (en) 2006-02-28
BR0215200A (pt) 2004-10-13
TWI262075B (en) 2006-09-21
CO5590896A2 (es) 2005-12-30
GB0130705D0 (en) 2002-02-06
IL162454A0 (en) 2005-11-20
CA2471461A1 (en) 2003-07-03
RU2318807C2 (ru) 2008-03-10
MY141579A (en) 2010-05-14
NO20042990L (no) 2004-09-20
EP1456172A1 (en) 2004-09-15
AU2002366747A1 (en) 2003-07-09
PL371008A1 (en) 2005-06-13
ZA200404147B (en) 2005-06-21

Similar Documents

Publication Publication Date Title
MXPA04006139A (es) Pirrolidin-2-onas como inhibidores del factor xa.
US10093683B2 (en) Factor XIa inhibitors
CN101374835B (zh) 作为PTPase抑制剂的取代的咪唑衍生物、组合物和使用方法
ES2303606T3 (es) Derivados de bencimidazol.
AU2021201924B2 (en) Human plasma kallikrein inhibitors
RU2398773C2 (ru) Арилоксизамещенное производное бензимидазола
AU2008205143A1 (en) Thiophene carboxamides as Factor Xa inhibitors
JP2011520915A (ja) グルコキナーゼ活性剤
WO2000009480A1 (en) Novel sulfonyl derivatives
JP2007523927A (ja) Ｘａ因子阻害剤としてのピロール誘導体
US7446210B2 (en) Factor Xa compounds
JP2001294572A (ja) 新規スルホニル誘導体
CZ20033325A3 (cs) Deriváty pyrrolidinu jako inhibitory faktoru Xa
SK9162001A3 (en) Substituted (aminoiminomethyl or aminomethyl)benzoheteroaryl compounds as factor xa inhibitors
MX2011004903A (es) Pirrolidinas.
ES2292820T3 (es) 2-(3-sulfonilamino-2-oxopyrrolidin-1-yl)propanamidas como inhibidores del factor xa.
CA3176142A1 (en) Phd inhibitor compounds, compositions, and use
US7482374B2 (en) Pyrrolidine-2-ones as Factor Xa inhibitors
JP2000119253A (ja) 新規なスルホニル誘導体
ZA200607219B (en) Urea derivatives
JP2000143623A (ja) 新規なスルホニル誘導体およびその塩
WO2004110435A1 (en) 1-phenyl-2-oxo-3-sulfonylamino-pyrrolidine derivatives and related compounds as factor xa inhibitors for the treatment of acute vascular diseases
US20070203206A1 (en) 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors
KR20070020400A (ko) 트롬빈 억제제로서 유용한 신규한 5,6-디히드로피리딘-2-온화합물
JP2007514742A (ja) トロンビンの阻害薬として有用な新規５，６−ジヒドロピリジン−２−オン化合物

Legal Events

Date Code Title Description
FG Grant or registration